Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.

作者：J. Wils, Herman O. Klein, D. J. Th. Wagener, Harry Bleiberg, Hans Edgar Reis, F.W. Korsten, T. Conroy, Martin M.F. Fickers, Serge Leyvraz, Marc E Buyse · 发表于：Journal of Clinical Oncology · 年份：1991 · DOI：10.1200/jco.1991.9.5.827 · 被引用次数：393 · 研究领域：Gastric Cancer Management and Outcomes、Colorectal Cancer Treatments and Studies、Helicobacter pylori-related gastroenterology studies

In a prospective phase III multicenter trial, 213 patients with advanced measurable or nonmeasurable gastric cancer were randomized to receive methotrexate (MTX), fluorouracil (5-FU), and Adriamycin (doxorubicin; Farmitalia Carlo Erba, Milan, Italy) (FAMTX) or 5-FU, Adriamycin, and mitomycin (FAM). The results show a significantly superior response rate (41% v 9% [P less than .0001]), and survival (median, 42 weeks v 29 weeks [P = .004]) for FAMTX. There was a cumulative thrombocytopenia in FAM and not in FAMTX. The FAMTX protocol should be the reference treatment in future clinical trials that seek to improve the therapeutic outcome in advanced gastric cancer.